Ellume’s at-home test costs about $30 and does not require a prescription. Users perform a nasal swab and insert the sample into an analyzer, with results sent to a smartphone about 15 minutes later.
The FDA approved Ellume’s test Dec. 15 after it demonstrated 96 percent accuracy in a U.S. clinical study. The agency has approved three at-home COVID-19 tests, but Ellume’s is the only one that doesn’t require a prescription. Currently, none are widely available.
The deal will help fund construction of Ellume’s first manufacturing facility in the U.S., with the goal of producing 640,000 tests per day by December. Ellume has committed to providing the U.S. with 8.5 million tests.
More articles on supply chain:
Bad batch of N95 masks may be counterfeit, Cleveland Clinic says
16-year-old pilot flies PPE to rural hospitals
FDA urged to review accuracy of pulse oximeters for people of color
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.